170 related articles for article (PubMed ID: 9067480)
21. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation.
Iyer SN; Hyde DM; Giri SN
Inflammation; 2000 Oct; 24(5):477-91. PubMed ID: 10921510
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats.
Corboz MR; Zhang J; LaSala D; DiPetrillo K; Li Z; Malinin V; Brower J; Kuehl PJ; Barrett TE; Perkins WR; Chapman RW
Pulm Pharmacol Ther; 2018 Apr; 49():95-103. PubMed ID: 29408757
[TBL] [Abstract][Full Text] [Related]
23. Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model.
Qin W; Liu B; Yi M; Li L; Tang Y; Wu B; Yuan X
Radiat Res; 2018 Oct; 190(4):396-403. PubMed ID: 30016220
[TBL] [Abstract][Full Text] [Related]
24. Cyclophosphamide Combined with Bone Marrow Mesenchymal Stromal Cells Protects against Bleomycin-induced Lung Fibrosis in Mice.
Xu J; Li L; Xiong J; Zheng Y; Ye Q; Li Y
Ann Clin Lab Sci; 2015; 45(3):292-300. PubMed ID: 26116593
[TBL] [Abstract][Full Text] [Related]
25. [Pirfenidone diminishes SiO2 induced lung fibrosis in rats].
Feng LF; Jia ZY; Zhu LJ; Ju L; Chen JQ; Jiang ZQ; Chen RP; Ma Z; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2010 Oct; 28(10):772-5. PubMed ID: 21126431
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, metabolic activation, and lung toxicity of cyclophosphamide in C57/B16 and ICR mice.
Kanekal S; Fraiser L; Kehrer JP
Toxicol Appl Pharmacol; 1992 May; 114(1):1-8. PubMed ID: 1585362
[TBL] [Abstract][Full Text] [Related]
27. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Antoniu SA
Expert Opin Investig Drugs; 2006 Jul; 15(7):823-8. PubMed ID: 16787145
[TBL] [Abstract][Full Text] [Related]
28. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
29. [The study of effects of pirfenidone on the pulmonary fibrosis induced by paraquat in mice].
Li JW; Shen XW; Sun W; Xiao M; Tong SH; Yu XC; Lu ZQ; Hu GX
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2011 Feb; 29(2):87-93. PubMed ID: 21619834
[TBL] [Abstract][Full Text] [Related]
30. Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis.
Ammar YA; Ismail MM; El-Sehrawi HM; Noaman E; Bayomi AH; Shawer TZ
Arch Pharm (Weinheim); 2006 Aug; 339(8):429-36. PubMed ID: 16832818
[TBL] [Abstract][Full Text] [Related]
31. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
32. Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis.
Meier R; Lutz C; Cosín-Roger J; Fagagnini S; Bollmann G; Hünerwadel A; Mamie C; Lang S; Tchouboukov A; Weber FE; Weber A; Rogler G; Hausmann M
Inflamm Bowel Dis; 2016 Mar; 22(3):569-82. PubMed ID: 26848518
[TBL] [Abstract][Full Text] [Related]
33. Effect of pirfenidone against vanadate-induced kidney fibrosis in rats.
Al-Bayati MA; Xie Y; Mohr FC; Margolin SB; Giri SN
Biochem Pharmacol; 2002 Aug; 64(3):517-25. PubMed ID: 12147304
[TBL] [Abstract][Full Text] [Related]
34. Mixed effects of 2,6-dithiopurine against cyclophosphamide mediated bladder and lung toxicity in mice.
Datta K; Chin A; Ahmed T; Qing WG; Powell KL; Simhambhatla P; MacLeod MC; Stoica G; Kehrer JP
Toxicology; 1998 Jan; 125(1):1-11. PubMed ID: 9585095
[TBL] [Abstract][Full Text] [Related]
35. Pirfenidone. First, do no harm.
Prescrire Int; 2013 May; 22(138):117-9. PubMed ID: 23819168
[TBL] [Abstract][Full Text] [Related]
36. EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts.
Li YJ; Azuma A; Usuki J; Abe S; Matsuda K; Sunazuka T; Shimizu T; Hirata Y; Inagaki H; Kawada T; Takahashi S; Kudoh S; Omura S
Respir Res; 2006 Jan; 7(1):16. PubMed ID: 16438734
[TBL] [Abstract][Full Text] [Related]
37. Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model.
Li G; Ren J; Hu Q; Deng Y; Chen G; Guo K; Li R; Li Y; Wu L; Wang G; Gu G; Li J
Biochem Pharmacol; 2016 Oct; 117():57-67. PubMed ID: 27498142
[TBL] [Abstract][Full Text] [Related]
38. Attenuation of bleomycin-induced lung fibrosis by oxymatrine is associated with regulation of fibroblast proliferation and collagen production in primary culture.
Chen X; Sun R; Hu J; Mo Z; Yang Z; Liao D; Zhong N
Basic Clin Pharmacol Toxicol; 2008 Sep; 103(3):278-86. PubMed ID: 18684219
[TBL] [Abstract][Full Text] [Related]
39. Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice.
Liu N; Song Y; Liu T; Wang H; Yu N; Ma H
Clin Respir J; 2024 Jan; 18(1):e13731. PubMed ID: 38286745
[TBL] [Abstract][Full Text] [Related]
40. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats.
Mirkovic S; Seymour AM; Fenning A; Strachan A; Margolin SB; Taylor SM; Brown L
Br J Pharmacol; 2002 Feb; 135(4):961-8. PubMed ID: 11861324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
